NasdaqCM - Nasdaq Real Time Price USD

Lipocine Inc. (LPCN)

4.5500

+0.1100

(+2.48%)

At close: April 25 at 4:00 PM EDT

4.7100

+0.16

(+3.52%)

After hours: April 25 at 4:57 PM EDT

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced results from a Phase 2 clinical trial (NCT04134091) which includes LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant. The results showed significant improvement in body composition through decreased FM and increased LM or fat free mass (FFM) in patients with BMI ≥ 30 (obese) or BMI ≥ 27 with at least one weight-related comorbidity.

PR Newswire 14 days ago
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company today announced positive topline results from a Phase 2 clinical study of LPCN 1148. LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopenia. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action (MOA). Lipocine plans to meet with the FDA to discuss a development path to NDA filing.

PR Newswire 28 days ago
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, oral brexanolone, is being developed by Lipocine for the treatment of postpartum depression (PPD).

PR Newswire last month
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results for the year ended December 31, 2023 and provided a corporate update.

PR Newswire last month
Lipocine to Present at 36th Annual Roth Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh V. Patel, President and Chief Executive Officer, will participate in a fireside chat and meet with investors at the 36th Annual Roth Conference, to take place in Laguna Niguel, CA, on March 18.

PR Newswire last month
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing regimen for the upcoming NDA enabling pivotal pharmacokinetic (PK) study. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression (PPD).

PR Newswire 2 months ago
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that commercialization of TLANDO® in the U.S. has been transitioned to its licensee Verity Pharma, effective February 1, 2024, enabling the continuity of patient access to TLANDO. TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration.

PR Newswire 2 months ago
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which Verity Pharma will market TLANDO® in the United States and, if approved, in Canada. TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that

PR Newswire 3 months ago
Lipocine to Present at Biotech Showcase 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and at a Corporate Access Event organized by LifeSci Partners. Both in-person events will take place January 8 - 10, 2024, in San Francisco, California.

PR Newswire 4 months ago
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, taking place in Boston MA. The results are featured in a late-breaking oral presentation and e-poster by Dr. Arun Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic He

PR Newswire 5 months ago
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update.

PR Newswire 5 months ago
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to take place in Boston MA, November 10 to 14, 2023.

PR Newswire 5 months ago
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced the completion of a meeting with the FDA and guidance for the appropriate acceptance criteria for the upcoming LPCN 1154 pivotal study.

PR Newswire 5 months ago
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023.

PR Newswire 5 months ago
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference to take place September 26th to September 28th in New York City.

PR Newswire 7 months ago
LPCN: Trial Results Improve Outlook

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2Q:23 Financial and Operational Results Two clinical trial readouts dominated Lipocine Inc.’s (NASDAQ:LPCN) news flow year to date: The pharmacokinetic (PK) study for LPCN 1154, which is in development for postpartum depression (PPD) and topline results from the Phase II study for LPCN 1148 in adult men with cirrhosis of the

Zacks Small Cap Research 8 months ago
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results for the second quarter and six months ended June 30, 2023, and provided a corporate update.

PR Newswire 8 months ago
LPCN: 1148 Shows Muscle Loss Reversal

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Lipocine Inc. (NASDAQ:LPCN) provided a pleasant surprise to investors with its strong Phase II results from its LPCN 1148 study as presented in a July 27th press release . A slide presentation was concurrently provided which can be accessed here . A The study was intended to measure the efficacy, safety and tolerability of

Zacks Small Cap Research 8 months ago
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced positive topline results from a Phase 2 clinical study of LPCN 1148. LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis. Lipocine plans to meet with the FDA to discuss a development path to NDA filing.

PR Newswire 8 months ago
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present virtually and meet with investors at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on June 26, 2023.

PR Newswire 10 months ago

Performance Overview

Return	LPCN	S&P 500
YTD	+63.08%	+5.84%
1-Year	-7.71%	+22.03%
3-Year	-81.79%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lipocine Inc. (LPCN)

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Lipocine to Present at 36th Annual Roth Conference

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Lipocine to Present at Biotech Showcase 2024

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

LPCN: Trial Results Improve Outlook

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

LPCN: 1148 Shows Muscle Loss Reversal

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

Performance Overview